{"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"15"}],"units":"Participants"}],"groups":[{"description":"Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally","id":"BG000","title":"Cohort A (Lenalidomide, Dexamethasone)"},{"description":"Patients with newly diagnosed multiple myeloma receive treatment as in Cohort A.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally","id":"BG001","title":"Cohort B (Lenalidomide, Dexamethasone)"},{"description":"Patients with relapsed or refractory multiple myeloma receive lenalidomide PO QD on days 1-14 in combination with dexamethasone PO QD on days 1, 8 and 15 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally\n\nPomalidomide: Given orally","id":"BG002","title":"Cohort C (Lenalidomide, Dexamethasone, Pomalidomide)"},{"description":"Patients with relapsed multiple myeloma after lenalidomide maintenance receive treatment as in Cohort C.\n\nBone Marrow Biopsy: Undergo bone marrow aspirate/biopsy\n\nDexamethasone: Given orally\n\nLenalidomide: Given orally\n\nPomalidomide: Given orally","id":"BG003","title":"Cohort D (Lenalidomide, Dexamethasone, Pomalidomide)"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG001","spread":"15.2","value":"61.4"},{"groupId":"BG002","spread":"12.1","value":"69.9"},{"groupId":"BG004","spread":"13.3","value":"67.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"10"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG004","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"},{"groupId":"BG004","value":"13"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG004","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG004","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"},{"groupId":"BG004","value":"12"}],"title":"White"},{"measurements":[{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG004","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"},{"groupId":"BG004","value":"15"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Only patients that completed the study were included in analysis"}